UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact nam ...

Nautilus Biotechnology (NasdaqGS:NAUT) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnna Mowry - CFOJi-Yon Yi - Director of Investor RelationsParag Mallick - Co-founder and Chief ScientistSujal Patel - Co-founder and CEOConference Call ParticipantsSubhasis Nambi - Equity Research AnalystNone - AnalystOperatorGood day, and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 2025 earnings conference call. At this time, all participants are in a listen-only mode. Afte ...

Nautilus Biotechnology (NasdaqGS:NAUT) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnna Mowry - CFOJi-Yon Yi - Director of Investor RelationsParag Mallick - Co-founder and Chief ScientistSujal Patel - Co-founder and CEOConference Call ParticipantsSubhasis Nambi - Equity Research AnalystNone - AnalystOperatorGood day, and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 2025 earnings conference call. At this time, all participants are in a listen-only mode. Afte ...

Nautilus Biotechnology (NasdaqGS:NAUT) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker2Good day, and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To wi ...

SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau data m ...

Exhibit 99.1 Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results SEATTLE, WA, February 26, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights "In Q4, Nautilus maintained disciplined execution and delivered meaningful progress across our platform develop ...

• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics • Researchers invited to apply to the Early Access Program to use Iterative Mapping, Nautilus’ technology designed to measure billions of intact protein molecules, ahead of broader commercial availability Nautilus Voyager™ Platform SEATTLE, Feb. 24, 2026 (GLO ...

Core Viewpoint - Nautilus Biotechnology, Inc. is participating in the TD Cowen 46 Annual Health Care Conference, highlighting its role in the life sciences sector focused on protein analysis [1]. Company Overview - Nautilus Biotechnology, Inc. is a development stage life sciences company headquartered in Seattle, Washington, with research and development operations in San Carlos, California [3]. - The company aims to create a platform technology for quantifying and understanding the complexity of the proteome, with a mission to democratize access to proteomics and advance human health and medicine [3]. Event Participation - Management of Nautilus is scheduled for a fireside chat on March 2, 2026, at 10:30 a.m. Eastern Time, which will be accessible via a live and archived webcast on the company's website [2].

Core Viewpoint - Nautilus Biotechnology, Inc. is set to report its financial results for Q4 and the full year of 2025 on February 26, 2026, before market opening [1] Company Overview - Nautilus Biotechnology, Inc. is a development stage life sciences company headquartered in Seattle, Washington, with research and development operations in San Carlos, California [3] - The company is focused on creating a platform technology aimed at quantifying and unlocking the complexity of the proteome, with a mission to democratize access to the proteome and facilitate advancements in human health and medicine [3]

• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new biological insights• Weill Cornell Medicine-Qatar’s deep chemical biology and neurology expertise and field-leading protein standards and affinity reagents position the organizations to probe disease-associated proteof ...